Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device
Catheter Precision, a wholly owned subsidiary of Flyte Aviation (NYSE American: VJET), announced the first published comparative study of its LockeT suture retention device versus Abbott's Perclose internal vascular closure device. In the 172-patient peer-reviewed study in The Journal of Interventional Cardiology, LockeT showed a 1.2% cumulative access-site complication rate versus 9.3% for Perclose, and a 0.0% device failure rate versus 4.7%. Both methods delivered similar time to hemostasis and same-day discharge rates.
Key figures
- Study patients
- 172
- Locket failure rate
- 0.0%
- Perclose failure rate
- 4.7%
- Locket complication rate
- 1.2%
- Perclose complication rate
- 9.3%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.